Live Analyst Rating Changes 1619 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Whitney Ijem
CG
Whitney Ijem
Canaccord Genuity
Wall Street Analyst
★★☆☆☆
#2144
on 13Foresight · ranked by our own returns
31%
Success Rate
-3.6%
Average Return
10 of 32 calls profitable · -10.8% vs benchmark
📈 Across the calls we could measure, roughly 31% of Whitney Ijem's ratings turned a profit when each position was held for 1 year — averaging -3.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

115 Buy 8 Hold 0 Sell
Whitney's Stock Coverage 32 ratings · 2026-06-22
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
NTLA
Intellia Therapeutics
 Jun 16, 2026 BUY Buy
+151.9% avg upside
37 analysts
$49.00
212.75% Upside
 ·
RYTM
Rhythm Pharmaceuticals
 Jun 16, 2026 BUY Strong Buy
+25.2% avg upside
19 analysts
$151.00
55.95% Upside
 +6.8%
RARE
Ultragenyx Pharmaceutical
 Jun 10, 2026 BUY Strong Buy
+142.1% avg upside
36 analysts
$79.00
187.89% Upside
 ·
GUTS
Fractyl Health, Inc.
 Jun 05, 2026 BUY Strong Buy
+449.9% avg upside
6 analysts
$8.00
832.06% Upside
 -1.3%
BBIO
BridgeBio Pharma
 Jun 03, 2026 BUY Strong Buy
+38.7% avg upside
34 analysts
$104.00
57.01% Upside
 +1.2%
OCGN
Ocugen
 May 27, 2026 BUY Strong Buy
+646.0% avg upside
17 analysts
$11.00
787.07% Upside
 ·
BMRN
BioMarin Pharmaceutical
 May 22, 2026 BUY Strong Buy
+72.8% avg upside
52 analysts
$111.00
102.91% Upside
 +1.7%
PVLA
Palvella Therapeutics
 May 21, 2026 BUY Strong Buy
+45.3% avg upside
27 analysts
$227.00
100.77% Upside
 -2.4%
BEAM
Beam Therapeutics
 May 21, 2026 BUY Strong Buy
+50.8% avg upside
25 analysts
$75.00
119.69% Upside
 +23.4%
WVE
Wave Life Sciences
 May 19, 2026 BUY Strong Buy
+260.5% avg upside
28 analysts
$43.00
598.08% Upside
 +0.3%
TNYA
Tenaya Therapeutics
 May 18, 2026 BUY Strong Buy
+1268.7% avg upside
11 analysts
$5.00
584.44% Upside
 ·
NGNE
Neurogene
 May 12, 2026 BUY Buy
+55.5% avg upside
23 analysts
$180.00
470.97% Upside
 -12.1%
ARCT
Arcturus Therapeutics
 May 08, 2026 BUY Buy
+290.9% avg upside
35 analysts
$21.00
178.84% Upside
 ·
PHAR
Pharming Group
 May 08, 2026 BUY Strong Buy
+199.1% avg upside
4 analysts
$37.00
187.34% Upside
 -2.8%
RCKT
Rocket Pharmaceuticals
 May 07, 2026 BUY Buy
+391.0% avg upside
29 analysts
$10.00
198.47% Upside
 -19.4%
TSHA
Taysha Gene Therapies
 May 06, 2026 BUY Strong Buy
+102.5% avg upside
21 analysts
$17.00
164.79% Upside
 -8.0%
VRTX
Vertex Pharmaceuticals
 May 05, 2026 HOLD Strong Buy
-2.6% avg upside
61 analysts
$436.00
3.43% Downside
 +8.2%
ALNY
Alnylam Pharma
 May 04, 2026 BUY Strong Buy
+23.6% avg upside
51 analysts
$429.00
54.18% Upside
 -5.1%
PASG
Passage Bio
 Apr 21, 2026 BUY Buy
+214.0% avg upside
14 analysts
$23.00
311.35% Upside
 -17.2%
KRYS
Krystal Biotech
 Feb 28, 2022 BUY Strong Buy
-28.2% avg upside
19 analysts
$114.00
67.18% Downside
 +28.9%
SRPT
Sarepta Therapeutics
 Sep 15, 2021 BUY Buy
+244.5% avg upside
49 analysts
 — +31.7%
GILD
Gilead Sciences
 Jan 04, 2021 BUY Strong Buy
-4.8% avg upside
66 analysts
 — +25.3%
INCY
Incyte
 Jan 04, 2021 BUY Buy
+1.5% avg upside
47 analysts
 — -16.9%
QURE
uniQure
 Jun 25, 2020 HOLD Strong Buy
+20.8% avg upside
29 analysts
 — -37.1%
MIRM
Mirum Pharmaceuticals
 Dec 16, 2019 BUY Strong Buy
+7.0% avg upside
21 analysts
$27.00
74.78% Downside
 ·
SGMO
Sangamo Therapeutics
 Nov 09, 2018 HOLD Buy
+5844.3% avg upside
16 analysts
$18.00
10215.22% Upside
 -11.7%
EDIT
Editas Medicine
 Oct 09, 2018 HOLD Buy
+408.0% avg upside
33 analysts
 — -28.3%
TECX
Tectonic Therapeutic
 Oct 09, 2018 BUY Strong Buy
+87.9% avg upside
24 analysts
$35.00
16.62% Upside
 -42.0%
CRSP
Crispr Therapeutics AG
 Oct 09, 2018 HOLD Buy
+39.1% avg upside
41 analysts
 — -0.3%
KPTI
Karyopharm Therapeutics
 May 04, 2017 BUY Strong Buy
+147.4% avg upside
18 analysts
$16.00
77.45% Upside
 +90.1%
TCRT
Alaunos Therapeutics
 Jan 11, 2017 HOLD Buy
+604.3% avg upside
13 analysts
 — -21.3%
MNKD
MannKind
 May 13, 2014 HOLD Buy
+78.6% avg upside
22 analysts
 — -44.8%
🔒 27 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Whitney Ijem — Frequently Asked Questions
How accurate are Whitney Ijem's stock ratings?
Based on the calls 13Foresight could measure, about 31% of Whitney's ratings were profitable over a one-year hold, with an average return of -3.6% per rating, or -10.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Whitney ranked on 13Foresight?
Whitney Ijem is currently ranked #2144 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Whitney cover?
Whitney most recently has ratings on NTLA, RYTM, RARE, GUTS, BBIO, OCGN, BMRN, PVLA, BEAM, WVE, TNYA, NGNE and 20 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.